<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29573139</article-id><article-id pub-id-type="pmc">5969323</article-id><article-id pub-id-type="doi">10.1111/dom.13296</article-id><article-id pub-id-type="publisher-id">DOM13296</article-id><article-id pub-id-type="other">DOM-17-0858-OP.R3</article-id><article-categories><subj-group subj-group-type="overline"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the <styled-content style="fixed-case">DURATION</styled-content>&#x02010;8 randomized controlled trial</article-title><alt-title alt-title-type="left-running-head">Fr&#x000ed;as et al.</alt-title></title-group><contrib-group><contrib id="dom13296-cr-0001" contrib-type="author" corresp="yes"><name><surname>Fr&#x000ed;as</surname><given-names>Juan P.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9486-1255</contrib-id><address><email>juan.frias@nritrials.com</email></address><xref ref-type="aff" rid="dom13296-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom13296-cr-0002" contrib-type="author"><name><surname>Hardy</surname><given-names>Elise</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13296-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13296-cr-0003" contrib-type="author"><name><surname>Ahmed</surname><given-names>Azazuddin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13296-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom13296-cr-0004" contrib-type="author"><name><surname>&#x000d6;hman</surname><given-names>Peter</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom13296-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13296-cr-0005" contrib-type="author"><name><surname>Jabbour</surname><given-names>Serge</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4080-0470</contrib-id><xref ref-type="aff" rid="dom13296-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom13296-cr-0006" contrib-type="author"><name><surname>Wang</surname><given-names>Hui</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom13296-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom13296-cr-0007" contrib-type="author"><name><surname>Guja</surname><given-names>Cristian</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8703-0522</contrib-id><xref ref-type="aff" rid="dom13296-aff-0005">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="dom13296-aff-0001" content-type="private-address">
<label><sup>1</sup></label>
<institution>National Research Institute</institution>
<named-content content-type="city">Los Angeles</named-content>
<named-content content-type="country-part">California</named-content>
</aff><aff id="dom13296-aff-0002" content-type="private-address">
<label><sup>2</sup></label>
<institution>AstraZeneca</institution>
<named-content content-type="city">Gaithersburg</named-content>
<named-content content-type="country-part">Maryland</named-content>
</aff><aff id="dom13296-aff-0003" content-type="private-address">
<label><sup>3</sup></label>
<institution>Apex Medical Research</institution>
<named-content content-type="city">Chicago</named-content>
<named-content content-type="country-part">Illinois</named-content>
</aff><aff id="dom13296-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Division of Endocrinology, Diabetes and Metabolic Diseases</named-content>
<institution>Sidney Kimmel Medical College of Thomas Jefferson University</institution>
<named-content content-type="city">Philadelphia</named-content>
<named-content content-type="country-part">Pennsylvania</named-content>
</aff><aff id="dom13296-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Diabetes, Nutrition and Metabolic Diseases</named-content>
<institution>Carol Davila University of Medicine and Pharmacy</institution>
<named-content content-type="city">Bucharest</named-content>
<country country="RO">Romania</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Juan P. Fr&#x000ed;as, MD, National Research Institute, 2010 Wilshire Boulevard, Suite #302, Los Angeles, CA 90057.<break/>
Email: <email>juan.frias@nritrials.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2018</year></pub-date><volume>20</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/dom.2018.20.issue-6</issue-id><fpage>1520</fpage><lpage>1525</lpage><history><date date-type="received"><day>17</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>15</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-20-1520.pdf"/><abstract><p>This analysis assessed whether responses with exenatide once weekly plus dapagliflozin (<italic>n</italic>&#x02009;=&#x02009;231), exenatide once weekly alone (<italic>n</italic>&#x02009;=&#x02009;230), or dapagliflozin alone (<italic>n</italic>&#x02009;=&#x02009;233) differed in key patient subpopulations of the DURATION&#x02010;8 trial. Potential treatment&#x02010;by&#x02010;subgroup interactions for changes in glycated haemoglobin (HbA1c) and body weight after 28&#x02009;weeks were evaluated among subgroups determined by baseline HbA1c, age, sex, body mass index, type 2 diabetes duration, race, ethnicity and estimated glomerular filtration rate (eGFR). Exenatide once weekly plus dapagliflozin reduced HbA1c and body weight across all subgroups: least&#x02010;squares mean reductions ranged from &#x02212;8.4 to &#x02212;26.1&#x02009;mmol/mol (&#x02212;0.77% to &#x02212;2.39%) for HbA1c and from &#x02212;2.07 to &#x02212;4.55&#x02009;kg for body weight. Potential treatment&#x02010;by&#x02010;subgroup interactions (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.10) were found for HbA1c change by age (<italic>P&#x02009;=</italic> .016) and eGFR (<italic>P&#x02009;=</italic> .097). Age subgroup analysis findings were not consistent with expected mechanistic effects, with the small number of patients aged &#x02265;65&#x02009;years (<italic>n</italic>&#x02009;=&#x02009;74 vs <italic>n</italic>&#x02009;=&#x02009;499 for patients aged &#x0003c;65&#x02009;years) limiting the interpretability of the interaction term. In the exenatide once weekly plus dapagliflozin and dapagliflozin groups, but not the exenatide once weekly group, HbA1c reductions were greater among patients with eGFR &#x02265;90 vs &#x02265;60 to &#x0003c;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> (least&#x02010;squares mean reductions of &#x02212;23.6 vs &#x02212;19.0&#x02009;mmol/mol [&#x02212;2.16% vs &#x02212;1.74%], &#x02212;17.3 vs &#x02212;12.0&#x02009;mmol/mol [&#x02212;1.58% vs &#x02212;1.10%], and &#x02212;17.7 vs &#x02212;16.9&#x02009;mmol/mol [&#x02212;1.62% vs &#x02212;1.55%] for the respective treatments); this was consistent with the mechanism of action of dapagliflozin. A potential treatment&#x02010;by&#x02010;subgroup interaction was observed for change in body weight by sex (<italic>P&#x02009;=</italic> .099), with greater weight loss for women vs men across all treatments (range&#x02009;&#x02212;2.56 to &#x02212;3.98&#x02009;kg vs &#x02212;0.56 to &#x02212;2.99&#x02009;kg). In conclusion, treatment with exenatide once weekly plus dapagliflozin reduced HbA1c and body weight across all patient subgroups and was more effective than exenatide once weekly or dapagliflozin alone in all adequately sized subgroups.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom13296-kwd-0001">dapagliflozin</kwd><kwd id="dom13296-kwd-0002">exenatide</kwd><kwd id="dom13296-kwd-0003"><styled-content style="fixed-case">GLP</styled-content>&#x02010;1 analogue</kwd><kwd id="dom13296-kwd-0004"><styled-content style="fixed-case">SGLT</styled-content>2 inhibitor</kwd><kwd id="dom13296-kwd-0005">type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="6"/><word-count count="3901"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom13296</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.8.2 mode:remove_FC converted:25.05.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="dom13296-cit-9001">
<string-name>
<surname>Fr&#x000ed;as</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION&#x02010;8 randomized controlled trial</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2018</year>;<volume>20</volume>:<fpage>1520</fpage>&#x02013;<lpage>1525</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.13296">https://doi.org/10.1111/dom.13296</ext-link>
<pub-id pub-id-type="pmid">29573139</pub-id></mixed-citation>
</p><fn-group><fn id="dom13296-note-1002"><p>
<bold>Funding information</bold> AstraZeneca</p></fn></fn-group></notes></front><body><sec id="dom13296-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Type 2 diabetes mellitus (T2DM) is a chronic, progressive illness with a strong genetic component that is caused by defects in multiple organ systems.<xref rid="dom13296-bib-0001" ref-type="ref">1</xref> Comorbidities and chronic complications are highly prevalent among people with T2DM,<xref rid="dom13296-bib-0002" ref-type="ref">2</xref> necessitating a multifactorial approach to management. In addition, other characteristics (such as age, sex, duration of disease, race and ethnicity) require individualization of patient care.<xref rid="dom13296-bib-0001" ref-type="ref">1</xref>, <xref rid="dom13296-bib-0002" ref-type="ref">2</xref>, <xref rid="dom13296-bib-0003" ref-type="ref">3</xref>, <xref rid="dom13296-bib-0004" ref-type="ref">4</xref>, <xref rid="dom13296-bib-0005" ref-type="ref">5</xref>
</p><p>Because of the progressive nature of T2DM, most patients will eventually require multiple therapies to achieve and maintain their individualized therapeutic targets.<xref rid="dom13296-bib-0004" ref-type="ref">4</xref> Several glucose&#x02010;lowering drug classes with complementary mechanisms of action are available. Two of the most recent classes are the glucagon&#x02010;like peptide&#x02010;1 receptor agonists (GLP&#x02010;1RAs) and the sodium&#x02010;glucose co&#x02010;transporter&#x02010;2 (SGLT2) inhibitors. The DURATION&#x02010;8 (Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention With Exenatide Once Weekly) trial showed that simultaneous initiation of the GLP&#x02010;1RA exenatide once weekly and the SGLT2 inhibitor dapagliflozin improved glycaemic control, systolic blood pressure and body weight over 28&#x02009;weeks compared with exenatide once weekly or dapagliflozin alone in patients with T2DM inadequately controlled by metformin.<xref rid="dom13296-bib-0006" ref-type="ref">6</xref> The aim of the present analysis was to determine whether the differences in glycated haemoglobin (HbA1c) and body weight responses seen in the overall population of DURATION&#x02010;8 differed among key patient subpopulations.</p></sec><sec id="dom13296-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="dom13296-sec-0003"><label>2.1</label><title>Study design</title><p>This was an analysis of data from the DURATION&#x02010;8 study (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">http://clinicaltrials.gov</ext-link> identifier: NCT02229396), the methods of which have previously been reported.<xref rid="dom13296-bib-0006" ref-type="ref">6</xref> DURATION&#x02010;8 enrolled adults (aged &#x02265;18&#x02009;years) with T2DM and inadequate glycaemic control (HbA1c 64&#x02010;108&#x02009;mmol/mol [8.0%&#x02010;12.0%]) despite receiving metformin monotherapy at a stable dose (&#x02265;1500&#x02009;mg/d) for at least 2&#x02009;months before screening. Patients were randomized to receive subcutaneous exenatide 2&#x02009;mg once weekly in combination with oral dapagliflozin 10&#x02009;mg once daily, exenatide once weekly plus oral placebo once daily, or dapagliflozin once daily plus subcutaneous placebo once weekly, all administered with background metformin, for 28&#x02009;weeks.</p><p>The original study protocol was developed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the ethics and regulatory committees and institutional review boards of the participating institutions.<xref rid="dom13296-bib-0006" ref-type="ref">6</xref> All patients provided written informed consent.</p></sec><sec id="dom13296-sec-0004"><label>2.2</label><title>Study outcomes and patient subgroups</title><p>The primary endpoint of DURATION&#x02010;8 was change in HbA1c from baseline to week 28, while change in body weight from baseline to week 28 was a secondary endpoint. In this analysis, changes from baseline to week 28 in HbA1c and body weight were assessed in various patient subgroups. Subgroups were defined by baseline HbA1c (&#x0003c;8.0%, &#x02265;8.0% to &#x0003c;9.0%, or &#x02265;9.0% [&#x0003c;64, &#x02265;64 to &#x0003c;75, or &#x02265;75 mmol/mol]), age (&#x0003c;65 or &#x02265;65&#x02009;years), sex, body mass index (BMI; &#x0003c;25, &#x02265;25 to &#x0003c;30, or &#x02265;30&#x02009;kg/m<sup>2</sup>), T2DM duration (&#x0003c;3, &#x02265;3 to &#x02264;10, or &#x0003e;10&#x02009;years), race (white, black/African American, Asian, American Indian/Alaskan native, or all other races), ethnicity (Hispanic/Latino or not Hispanic/Latino), and estimated glomerular filtration rate (eGFR; &#x0003c;60, &#x02265;60 to &#x0003c;90, or &#x02265;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>).</p></sec><sec id="dom13296-sec-0005"><label>2.3</label><title>Statistical analysis</title><p>Least&#x02010;squares mean changes in HbA1c and body weight for treatment groups were calculated using a mixed&#x02010;effects model for repeated measures analysis, with treatment, country, baseline HbA1c stratum, baseline HbA1c and body weight, week, subgroup, treatment&#x02010;by&#x02010;week, subgroup&#x02010;by&#x02010;week, subgroup&#x02010;by&#x02010;treatment, and subgroup&#x02010;by&#x02010;week&#x02010;by&#x02010;treatment interactions as fixed factors. Nominal <italic>P</italic> values for treatment&#x02010;by&#x02010;subgroup interactions were reported, with <italic>P</italic>&#x02009;&#x0003c;&#x02009;.10 considered indicative of a potential treatment&#x02010;by&#x02010;subgroup interaction; this conservative threshold is commonly employed to ensure adequate sensitivity to detect interactions because of the reduced power within subgroups. There was no correction for multiplicity.</p></sec></sec><sec id="dom13296-sec-0006"><label>3</label><title>RESULTS</title><p>Of 695 randomized patients, one did not receive study medication, leaving 231, 230 and 233 patients in the exenatide once weekly plus dapagliflozin, exenatide once weekly and dapagliflozin groups, respectively. Baseline characteristics were similar among treatment groups, with the exception of fewer women in the exenatide once weekly group and fewer Hispanic/Latino patients in the dapagliflozin group.<xref rid="dom13296-bib-0006" ref-type="ref">6</xref>
</p><sec id="dom13296-sec-0007"><label>3.1</label><title>Change in <styled-content style="fixed-case">HbA1c</styled-content>
</title><p>Clinically relevant HbA1c reductions were observed with all treatments across all subgroups. HbA1c reductions were greater with exenatide once weekly plus dapagliflozin than with either exenatide once weekly or dapagliflozin alone in all adequately sized subgroups.</p><p>After 28&#x02009;weeks, HbA1c was reduced with all treatments across all baseline HbA1c subgroups, with no evidence of a treatment&#x02010;by&#x02010;subgroup interaction (<italic>P</italic>&#x02009;=&#x02009;.978; Table <xref rid="dom13296-tbl-0001" ref-type="table-wrap">1</xref>). HbA1c reductions were greater with increasing baseline HbA1c. Small numbers of patients in the HbA1c &#x0003c;8.0% (&#x0003c;64 mmol/mol) subgroup limited the interpretability of the interaction <italic>P</italic> value.</p><table-wrap id="dom13296-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Change in HbA1c (mmol/mol) from baseline to week 28 by subgroup</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><thead valign="middle"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="middle" rowspan="1" colspan="1">Baseline subgroup</th><th align="left" valign="middle" rowspan="1" colspan="1">Exenatide once weekly&#x02009;+&#x02009;dapagliflozin</th><th align="left" valign="middle" rowspan="1" colspan="1">Exenatide once weekly&#x02009;+&#x02009;placebo</th><th align="left" valign="middle" rowspan="1" colspan="1">Dapagliflozin&#x02009;+&#x02009;placebo</th><th align="left" valign="middle" rowspan="1" colspan="1">Interaction <italic>P</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c<xref ref-type="fn" rid="dom13296-note-0004">a</xref> (<italic>n</italic> for subgroups)</td><td align="left" valign="top" rowspan="1" colspan="1">(11/74/108)</td><td align="left" valign="top" rowspan="1" colspan="1"> (13/71/100)</td><td align="left" valign="top" rowspan="1" colspan="1">(14/76/106)</td><td align="char" valign="top" rowspan="1" colspan="1">.978</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;8.0% (&#x0003c;64&#x02009;mmol/mol)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;16.7&#x02009;&#x000b1;&#x02009;4.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;7.5&#x02009;&#x000b1;&#x02009;3.9</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;10.8&#x02009;&#x000b1;&#x02009;3.8</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x02265;8.0 to &#x0003c;9.0% (&#x02265;64 to &#x0003c;75&#x02009;mmol/mol)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;18.0&#x02009;&#x000b1;&#x02009;1.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;13.7&#x02009;&#x000b1;&#x02009;1.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;10.7&#x02009;&#x000b1;&#x02009;1.6</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x02265;9.0% (&#x02265;75&#x02009;mmol/mol)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;24.7&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;21.4&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;19.0&#x02009;&#x000b1;&#x02009;1.3</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (<italic>n</italic> for subgroups)</td><td align="left" valign="top" rowspan="1" colspan="1">(13/63/117)</td><td align="left" valign="top" rowspan="1" colspan="1">(12/65/107)</td><td align="left" valign="top" rowspan="1" colspan="1">(12/49/135)</td><td align="char" valign="top" rowspan="1" colspan="1">.906</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;25&#x02009;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;23.1&#x02009;&#x000b1;&#x02009;3.7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;20.4&#x02009;&#x000b1;&#x02009;3.8</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;20.1&#x02009;&#x000b1;&#x02009;3.9</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x02265;25 to &#x0003c;30&#x02009;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;20.6&#x02009;&#x000b1;&#x02009;1.7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;16.5&#x02009;&#x000b1;&#x02009;1.7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;14.1&#x02009;&#x000b1;&#x02009;2.0</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x02265;30&#x02009;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;22.1&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.8&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;15.1&#x02009;&#x000b1;&#x02009;1.2</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (<italic>n</italic> for subgroups)</td><td align="left" valign="top" rowspan="1" colspan="1"> (84/109)</td><td align="left" valign="top" rowspan="1" colspan="1">(96/88)</td><td align="left" valign="top" rowspan="1" colspan="1">(93/103)</td><td align="char" valign="top" rowspan="1" colspan="1">.550</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Men</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;21.0&#x02009;&#x000b1;&#x02009;1.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.7&#x02009;&#x000b1;&#x02009;1.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;15.8&#x02009;&#x000b1;&#x02009;1.4</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;22.2&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.4&#x02009;&#x000b1;&#x02009;1.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;14.6&#x02009;&#x000b1;&#x02009;1.4</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race (<italic>n</italic> for subgroups)</td><td align="left" valign="top" rowspan="1" colspan="1">(161/28/3/0/1)</td><td align="left" valign="top" rowspan="1" colspan="1">(161/20/1/2/0)</td><td align="left" valign="top" rowspan="1" colspan="1"> (165/24/1/0/6)</td><td align="char" valign="top" rowspan="1" colspan="1">.645</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;21.3&#x02009;&#x000b1;&#x02009;1.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.3&#x02009;&#x000b1;&#x02009;1.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;15.0&#x02009;&#x000b1;&#x02009;1.2</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black/African American</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;23.6&#x02009;&#x000b1;&#x02009;2.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;18.8&#x02009;&#x000b1;&#x02009;3.0</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;13.0&#x02009;&#x000b1;&#x02009;2.6</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;8.4&#x02009;&#x000b1;&#x02009;8.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.7&#x02009;&#x000b1;&#x02009;14.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;15.3&#x02009;&#x000b1;&#x02009;14.4</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">American Indian/Alaskan Native</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;9.1&#x02009;&#x000b1;&#x02009;10.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;19.1&#x02009;&#x000b1;&#x02009;14.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;24.8&#x02009;&#x000b1;&#x02009;5.9</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ethnicity (<italic>n</italic> for subgroups)</td><td align="left" valign="top" rowspan="1" colspan="1">(76/117)</td><td align="left" valign="top" rowspan="1" colspan="1"> (68/116)</td><td align="left" valign="top" rowspan="1" colspan="1">(72/124)</td><td align="char" valign="top" rowspan="1" colspan="1">.396</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic/Latino</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;17.9&#x02009;&#x000b1;&#x02009;1.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;14.8&#x02009;&#x000b1;&#x02009;1.7</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;14.6&#x02009;&#x000b1;&#x02009;1.7</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;Hispanic/Latino</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;23.5&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;18.7&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;15.0&#x02009;&#x000b1;&#x02009;1.2</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T2DM duration (<italic>n</italic> for subgroups)</td><td align="left" valign="top" rowspan="1" colspan="1">(42/100/51)</td><td align="left" valign="top" rowspan="1" colspan="1">(42/101/41)</td><td align="left" valign="top" rowspan="1" colspan="1"> (40/110/46)</td><td align="char" valign="top" rowspan="1" colspan="1">.633</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003c;3&#x02009;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;24.4&#x02009;&#x000b1;&#x02009;2.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;20.6&#x02009;&#x000b1;&#x02009;2.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;19.5&#x02009;&#x000b1;&#x02009;2.1</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x02265;3 to &#x02264;10&#x02009;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;20.3&#x02009;&#x000b1;&#x02009;1.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;16.9&#x02009;&#x000b1;&#x02009;1.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;14.4&#x02009;&#x000b1;&#x02009;1.3</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;10&#x02009;years</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;21.5&#x02009;&#x000b1;&#x02009;2.0</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;16.0&#x02009;&#x000b1;&#x02009;2.1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;12.4&#x02009;&#x000b1;&#x02009;2.1</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="dom13296-note-0002"><p>Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus.</p></fn><fn id="dom13296-note-0003"><p>Data are least&#x02010;squares mean&#x02009;&#x000b1;&#x02009;standard error, unless otherwise specified. Conversion calculator for HbA1c (mmol/mol to %): <ext-link ext-link-type="uri" xlink:href="http://www.ngsp.org/convert2.asp">http://www.ngsp.org/convert2.asp</ext-link>
</p></fn><fn id="dom13296-note-0004"><label>a</label><p>Study inclusion criteria required patients to have an HbA1c of 64 to 108&#x02009;mmol/mol (8.0%&#x02010;12.0%) at screening, but HbA1c decreased to &#x0003c;64&#x02009;mmol/mol (&#x0003c;8.0%) between screening and baseline measurements in some patients.</p></fn></table-wrap-foot></table-wrap><p>A potential treatment&#x02010;by&#x02010;subgroup interaction was observed for HbA1c change by baseline age subgroup (<italic>P&#x02009;=</italic> .016; Figure <xref rid="dom13296-fig-0001" ref-type="fig">1</xref>A), although there were too few patients aged &#x02265;65&#x02009;years in each treatment group for this to be conclusive. HbA1c reductions were greater for patients aged &#x02265;65&#x02009;years vs &#x0003c;65&#x02009;years with exenatide once weekly plus dapagliflozin, while this relationship was reversed for exenatide once weekly alone and dapagliflozin alone (Figure <xref rid="dom13296-fig-0001" ref-type="fig">1</xref>A).</p><fig fig-type="Figure" xml:lang="en" id="dom13296-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Glycated haemoglobin (HbA1c) decrease from baseline to week 28 according to A, baseline age subgroups (&#x0003c;65 or &#x02265;65&#x02009;years) and B, baseline estimated glomerular filtration rate (eGFR) subgroups (&#x0003c;60, &#x02265;60 to &#x0003c;90, or &#x02265;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>). LSM, least&#x02010;squares mean; SE, standard error. Conversion calculator for HbA1c (mmol/mol to %): <ext-link ext-link-type="uri" xlink:href="http://www.ngsp.org/convert2.asp">http://www.ngsp.org/convert2.asp</ext-link>
</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-20-1520-g001"/></fig><p>Reductions in HbA1c were observed in all treatment groups across all baseline BMI and T2DM duration subgroups (Table <xref rid="dom13296-tbl-0001" ref-type="table-wrap">1</xref>), with no evidence of treatment&#x02010;by&#x02010;subgroup interactions. By contrast, a potential treatment&#x02010;by&#x02010;subgroup interaction was observed for HbA1c change by baseline eGFR (<italic>P</italic>&#x02009;=&#x02009;.097; Figure <xref rid="dom13296-fig-0001" ref-type="fig">1</xref>B). HbA1c reductions were greater for patients with eGFR &#x02265;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> vs &#x02265;60 to &#x0003c;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> in the exenatide once weekly plus dapagliflozin and dapagliflozin alone groups, whereas this pattern was not observed with exenatide once weekly alone. In addition, sex, race or ethnicity did not differentially affect the improvements in HbA1c observed with the three treatments (Table <xref rid="dom13296-tbl-0001" ref-type="table-wrap">1</xref>); however, the interpretability of the interaction term for the race subgroup was limited by the small numbers in some of the race subgroups.</p></sec><sec id="dom13296-sec-0008"><label>3.2</label><title>Change in body weight</title><p>Body weight decreased from baseline with all three treatments in all subgroups (Table <xref rid="dom13296-supitem-0001" ref-type="supplementary-material">S1</xref>); greater reductions were seen with exenatide once weekly plus dapagliflozin than with exenatide once weekly or dapagliflozin alone across all adequately sized subgroups. A potential treatment&#x02010;by&#x02010;subgroup interaction was found for sex (<italic>P&#x02009;=</italic> .099; Table <xref rid="dom13296-supitem-0001" ref-type="supplementary-material">S1</xref>), related to the smaller reduction in body weight observed among men in the group receiving exenatide once weekly alone. In all treatment groups, body weight reductions were greater for women than men. Reductions in body weight were numerically greater for patients with baseline HbA1c &#x02265;8.0% to &#x0003c;9.0% (&#x02265;64 to &#x0003c;75 mmol/mol) compared with &#x02265;9.0% (&#x02265;75 mmol/mol) in the groups receiving exenatide once weekly plus dapagliflozin or exenatide once weekly alone, although evidence of a treatment&#x02010;by&#x02010;subgroup interaction (<italic>P&#x02009;=</italic> .918) was not observed. As with the analysis of HbA1c change, small patient numbers in the HbA1c &#x0003c;8.0% (&#x0003c;64 mmol/mol) subgroup limited the interpretability of the interaction <italic>P</italic> value in this subgroup.</p></sec></sec><sec id="dom13296-sec-0009"><label>4</label><title>DISCUSSION</title><p>The results of the present analysis show that the combination of exenatide once weekly plus dapagliflozin was effective in reducing HbA1c and body weight irrespective of sex, age, body weight, race, ethnicity or disease characteristics. While a potential treatment&#x02010;by&#x02010;subgroup interaction was observed between age and the HbA1c change, the subgroup of patients aged &#x02265;65&#x02009;years was small, which limited the interpretability of the interaction term. Moreover, the results did not suggest a mechanistic explanation for differences according to age and, therefore, should be interpreted with caution. As expected, a potential treatment&#x02010;by&#x02010;subgroup interaction was observed for change in HbA1c by eGFR in the dapagliflozin&#x02010;containing treatment groups; HbA1c reductions were greater for patients with eGFR &#x02265;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> vs eGFR &#x02265;60 to &#x0003c;90&#x02009;mL/min/1.73&#x02009;m<sup>2</sup>, consistent with the mechanism of action of dapagliflozin, which blocks the reabsorption of glucose in the kidney and is dependent on plasma glucose and glomerular filtration rate. The small number of patients with eGFR &#x0003c;60&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> limited the interpretability of these findings. Weight loss appeared greater for patients with baseline HbA1c &#x02265;8.0% to &#x0003c;9.0% (&#x02265;64 to &#x0003c;75&#x02009;mmol/mol) vs &#x02265;9.0% (&#x02265;75&#x02009;mmol/mol), potentially because higher baseline HbA1c was associated with a catabolic state and weight loss was attenuated by improved glycaemic control, with improvement in catabolic state<xref rid="dom13296-bib-0006" ref-type="ref">6</xref>; there were few patients with baseline HbA1c &#x0003c;8.0% (&#x0003c;64&#x02009;mmol/mol), which limits the interpretability of the interaction <italic>P</italic> value. Finally, there was evidence of a potential interaction between sex and body weight change. Weight loss was greater among women than men; however, this potential interaction may be related to the smaller&#x02010;than&#x02010;expected weight loss in men receiving exenatide once weekly.</p><p>As expected, the combination of exenatide once weekly plus dapagliflozin reduced HbA1c and body weight more than either drug alone across all adequately sized subgroups. This was consistent with the results for the overall study population, in which exenatide once weekly plus dapagliflozin produced significantly greater reductions in HbA1c and body weight than exenatide once weekly or dapagliflozin alone (&#x02212;21.9 vs &#x02212;17.5 and&#x02009;&#x02212;&#x02009;15.3&#x02009;mmol/mol [&#x02212;2.0%, &#x02212;1.6% and &#x02212;1.4%] and &#x02212;3.55 vs &#x02212;1.56 and &#x02212;2.22&#x02009;kg, respectively).<xref rid="dom13296-bib-0006" ref-type="ref">6</xref> To date, the DURATION&#x02010;8 study is the only randomized controlled trial of an SGLT2 inhibitor and GLP&#x02010;1RA combination in patients with T2DM for which results have been published. However, another study examined the effects of this combination in individuals with obesity without T2DM and found that those treated with exenatide once weekly plus dapagliflozin had a significantly greater reduction in body weight after 24&#x02009;weeks than the placebo group (&#x02212;4.48 vs &#x02212;0.35&#x02009;kg, respectively).<xref rid="dom13296-bib-0007" ref-type="ref">7</xref> Results from the AWARD&#x02010;10 study (NCT02597049), when available, will provide further information on the effects of combination therapy with these two glucose&#x02010;lowering therapy classes.</p><p>This analysis was not designed to make statistical comparisons between treatments within each subgroup or to identify subgroups in which a treatment was more or less effective than in the overall intention&#x02010;to&#x02010;treat population; however, to the best of our knowledge, this is the first analysis evaluating potential treatment&#x02010;by&#x02010;subgroup interactions for concomitant administration of a GLP&#x02010;1RA/SGLT2 inhibitor combination in patients with T2DM. Furthermore, there are several published reports investigating the effects of a GLP&#x02010;1RA or SGLT2 inhibitor individually according to various baseline characteristics.</p><p>Analyses of exenatide twice daily treatment have shown that reductions in HbA1c and body weight are generally unaffected by baseline HbA1c or baseline BMI<xref rid="dom13296-bib-0008" ref-type="ref">8</xref>, <xref rid="dom13296-bib-0009" ref-type="ref">9</xref>, <xref rid="dom13296-bib-0010" ref-type="ref">10</xref>; however, one study found that patients with a T2DM duration of &#x0003e;15&#x02009;years lost more weight with exenatide twice daily vs placebo than patients with a shorter disease duration.<xref rid="dom13296-bib-0008" ref-type="ref">8</xref> In a study investigating exenatide twice daily and once weekly, HbA1c reductions with exenatide twice daily were greater among Asian patients vs white patients (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.0001), but weight loss was greater among white patients.<xref rid="dom13296-bib-0011" ref-type="ref">11</xref> There was no effect of race on HbA1c reduction with exenatide once weekly in this study, although white patients lost more weight than Asian patients with exenatide once weekly.<xref rid="dom13296-bib-0011" ref-type="ref">11</xref> A pooled analysis of the effect of exenatide once weekly according to age, sex, race, T2DM duration, and BMI showed no differences in HbA1c and body weight reductions in any of the subpopulations investigated.<xref rid="dom13296-bib-0012" ref-type="ref">12</xref> Although some studies investigating treatment with exenatide twice daily<xref rid="dom13296-bib-0010" ref-type="ref">10</xref> or dulaglutide<xref rid="dom13296-bib-0013" ref-type="ref">13</xref> showed no impact of sex on the change in body weight in people with T2DM, recent analyses of dulaglutide data found weight loss was greater for women than men.<xref rid="dom13296-bib-0014" ref-type="ref">14</xref>, <xref rid="dom13296-bib-0015" ref-type="ref">15</xref>
</p><p>There are also studies evaluating the effect of baseline characteristics on SGLT2 inhibitor efficacy. Analyses of canagliflozin data suggest that reductions in HbA1c and body weight with canagliflozin are not affected by race<xref rid="dom13296-bib-0016" ref-type="ref">16</xref>, <xref rid="dom13296-bib-0017" ref-type="ref">17</xref>; however, HbA1c reductions were greater in patients with a higher baseline HbA1c than those with a lower baseline HbA1c.<xref rid="dom13296-bib-0018" ref-type="ref">18</xref> A pooled analysis of the effect of dapagliflozin on cardiovascular risk factors according to eGFR confirmed the decreased efficacy in reducing HbA1c among patients with eGFR &#x02265;45 to &#x0003c;60&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> compared with those with eGFR &#x02265;60 to &#x0003c;90 or&#x02009;&#x02265;&#x02009;90 mL/min/1.73&#x02009;m<sup>2</sup> (interaction <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001), with no influence on the effect of treatment on body weight.<xref rid="dom13296-bib-0019" ref-type="ref">19</xref> Finally, an interim analysis of the ASSIGN&#x02010;K study showed no relationship between sex and weight loss in Japanese patients with T2DM.<xref rid="dom13296-bib-0020" ref-type="ref">20</xref>
</p><p>The present analysis has some limitations. Primarily, the small size of some subpopulations limited the interpretability of the results. Some weight analyses were performed post hoc, with the inherent limitations of such analyses. Furthermore, there was no adjustment for multiplicity.</p><p>In conclusion, treatment with exenatide once weekly plus dapagliflozin reduced HbA1c and body weight across all patient subgroups and was more effective than exenatide once weekly or dapagliflozin alone in all adequately sized subgroups. This was consistent with the results for the overall study population. Potential treatment&#x02010;by&#x02010;subgroup interactions were observed for age and eGFR when evaluating changes in HbA1c, and for sex when evaluating changes in body weight. No other treatment&#x02010;by&#x02010;subgroup interactions were observed.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom13296-supitem-0001"><caption><p>
<bold>Table S1.</bold> Change in body weight (kg) from baseline to week 28 by subgroup.</p></caption><media xlink:href="DOM-20-1520-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom13296-sec-0010"><title>ACKNOWLEDGMENTS</title><p>Sheridan Henness, PhD, and Simone Boniface of inScience Communications, Springer Healthcare (Auckland, New Zealand) provided medical writing support in accordance with Good Publication Practice, funded by AstraZeneca.</p><sec id="dom13296-sec-0011" sec-type="COI-statement"><title>Conflict of interest</title><p>J. P. F. has received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Eli Lilly, IONIS, Janssen, Johnson &#x00026; Johnson, Ligand, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Theracos and vTv Therapeutics, and has participated in the scientific advisory boards for and received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb, Novo Nordisk, Sanofi and Theracos. E. H. and P. &#x000d6;. are employees of AstraZeneca. A. A. has received research grants to conduct clinical trials from AbbVie, AstraZeneca, Kowa Pharmaceuticals, Novo Nordisk and Sanofi Aventis. S. J. has acted as a consultant for AstraZeneca, Eli Lilly and Janssen. H. W. is a consultant for AstraZeneca. C. G. has participated in scientific advisory boards for and received consulting fees from Alfa Wasserman, AstraZeneca, Bayer AG, Berlin&#x02010;Chemie Mennarini, Eli Lilly, Merck Sharp &#x00026; Dohme, Novo Nordisk and Sanofi.</p></sec><sec id="dom13296-sec-0012"><title>Author contributions</title><p>J. P. F., E. H., A. A., P. &#x000d6;., S. J. and C. G. contributed to the acquisition of study data and the analysis and interpretation of the data. J. P. F., A. A., S. J. and C. G. were study investigators. H. W. contributed to the analysis and interpretation of the data. All authors provided critical review of the manuscript and read and approved the final version.</p></sec></ack><ref-list id="dom13296-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="dom13296-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom13296-cit-0001">
<collab collab-type="authors">American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes&#x02014;2017</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2017</year>;<volume>40</volume>:<fpage>S1</fpage>&#x02010;<lpage>S135</lpage>.<pub-id pub-id-type="pmid">27979885</pub-id></mixed-citation></ref><ref id="dom13296-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom13296-cit-0002">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, et al. <article-title>Management of hyperglycemia in type 2 diabetes: a patient&#x02010;centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2012</year>;<volume>35</volume>:<fpage>1364</fpage>&#x02010;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">22517736</pub-id></mixed-citation></ref><ref id="dom13296-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom13296-cit-0003">
<string-name>
<surname>Bailey</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Day</surname>
<given-names>C</given-names>
</string-name>. <article-title>Diabetes therapies in renal impairment</article-title>. <source xml:lang="en">Br J Diabetes Vasc Dis</source>. <year>2012</year>;<volume>12</volume>:<fpage>167</fpage>&#x02010;<lpage>171</lpage>.</mixed-citation></ref><ref id="dom13296-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom13296-cit-0004">
<string-name>
<surname>Inzucchi</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Buse</surname>
<given-names>JB</given-names>
</string-name>, et al. <article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient&#x02010;centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>140</fpage>&#x02010;<lpage>149</lpage>.<pub-id pub-id-type="pmid">25538310</pub-id></mixed-citation></ref><ref id="dom13296-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom13296-cit-0005">
<string-name>
<surname>Clemens</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shariff</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schernthaner</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tangri</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Garg</surname>
<given-names>AX</given-names>
</string-name>. <article-title>Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004&#x02010;2013</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>607</fpage>&#x02010;<lpage>614</lpage>.<pub-id pub-id-type="pmid">26939711</pub-id></mixed-citation></ref><ref id="dom13296-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom13296-cit-0006">
<string-name>
<surname>Fr&#x000ed;as</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Guja</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION&#x02010;8): a 28 week, multicentre, double&#x02010;blind, phase 3, randomised controlled trial</article-title>. <source xml:lang="en">Lancet Diabetes Endocrinol</source>. <year>2016</year>;<volume>4</volume>:<fpage>1004</fpage>&#x02010;<lpage>1016</lpage>.<pub-id pub-id-type="pmid">27651331</pub-id></mixed-citation></ref><ref id="dom13296-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom13296-cit-0007">
<string-name>
<surname>Lundkvist</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Amini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Dapagliflozin once&#x02010;daily and exenatide once&#x02010;weekly dual therapy: a 24&#x02010;week randomized, placebo&#x02010;controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>:<fpage>49</fpage>&#x02010;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27550386</pub-id></mixed-citation></ref><ref id="dom13296-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom13296-cit-0008">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shenouda</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Bergenstal</surname>
<given-names>RM</given-names>
</string-name>, et al. <article-title>Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes</article-title>. <source xml:lang="en">Diabetes Care</source>. <year>2012</year>;<volume>35</volume>:<fpage>955</fpage>&#x02010;<lpage>958</lpage>.<pub-id pub-id-type="pmid">22432107</pub-id></mixed-citation></ref><ref id="dom13296-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom13296-cit-0009">
<string-name>
<surname>Wolffenbuttel</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Van Gaal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Duran&#x02010;Garcia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>. <article-title>Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>829</fpage>&#x02010;<lpage>833</lpage>.<pub-id pub-id-type="pmid">27027802</pub-id></mixed-citation></ref><ref id="dom13296-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom13296-cit-0010">
<string-name>
<surname>Pencek</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Blickensderfer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Brunell</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>PW</given-names>
</string-name>. <article-title>Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index</article-title>. <source xml:lang="en">Postgrad Med</source>. <year>2012</year>;<volume>124</volume>:<fpage>21</fpage>&#x02010;<lpage>32</lpage>.</mixed-citation></ref><ref id="dom13296-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom13296-cit-0011">
<string-name>
<surname>Sheu</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Brunell</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Blase</surname>
<given-names>E</given-names>
</string-name>. <article-title>Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus white patients with type 2 diabetes mellitus: a pooled analysis</article-title>. <source xml:lang="en">Diabetes Res Clin Pract</source>. <year>2016</year>;<volume>114</volume>:<fpage>160</fpage>&#x02010;<lpage>172</lpage>.<pub-id pub-id-type="pmid">26827116</pub-id></mixed-citation></ref><ref id="dom13296-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom13296-cit-0012">
<string-name>
<surname>Pencek</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Blickensderfer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Brunell</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>. <article-title>Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations</article-title>. <source xml:lang="en">Int J Clin Pract</source>. <year>2012</year>;<volume>66</volume>:<fpage>1021</fpage>&#x02010;<lpage>1032</lpage>.<pub-id pub-id-type="pmid">22925173</pub-id></mixed-citation></ref><ref id="dom13296-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom13296-cit-0013">
<string-name>
<surname>Umpierrez</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>Pantalone</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Kwan</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Zimmermann</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fernandez Lando</surname>
<given-names>L</given-names>
</string-name>. <article-title>Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once&#x02010;weekly dulaglutide treatment</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>615</fpage>&#x02010;<lpage>622</lpage>.<pub-id pub-id-type="pmid">26969812</pub-id></mixed-citation></ref><ref id="dom13296-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom13296-cit-0014">
<string-name>
<surname>Gallwitz</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dagogo&#x02010;Jack</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thieu</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Effect of once&#x02010;weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c</article-title>. <source xml:lang="en">Diabetes Obes Metab</source>. <year>2018</year>;<volume>20</volume>:<fpage>409</fpage>&#x02010;<lpage>418</lpage>.<pub-id pub-id-type="pmid">28817231</pub-id></mixed-citation></ref><ref id="dom13296-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom13296-cit-0015">
<string-name>
<surname>Onishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishiyama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ohyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iwamoto</surname>
<given-names>N</given-names>
</string-name>. <article-title>Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes</article-title>. <source xml:lang="en">Endocr J</source>. <year>2016</year>;<volume>63</volume>:<fpage>263</fpage>&#x02010;<lpage>273</lpage>.<pub-id pub-id-type="pmid">26698689</pub-id></mixed-citation></ref><ref id="dom13296-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom13296-cit-0016">
<string-name>
<surname>Davidson</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Aguilar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lavalle Gonzalez</surname>
<given-names>FJ</given-names>
</string-name>, et al. <article-title>Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity</article-title>. <source xml:lang="en">Ethn Dis</source>. <year>2016</year>;<volume>26</volume>:<fpage>221</fpage>&#x02010;<lpage>228</lpage>.<pub-id pub-id-type="pmid">27103773</pub-id></mixed-citation></ref><ref id="dom13296-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom13296-cit-0017">
<string-name>
<surname>Gavin</surname>
<given-names>JR</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vijapurkar</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Alba</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Meininger</surname>
<given-names>G</given-names>
</string-name>. <article-title>The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus</article-title>. <source xml:lang="en">Curr Med Res Opin</source>. <year>2015</year>;<volume>31</volume>:<fpage>1693</fpage>&#x02010;<lpage>1702</lpage>.<pub-id pub-id-type="pmid">26121561</pub-id></mixed-citation></ref><ref id="dom13296-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom13296-cit-0018">
<string-name>
<surname>Wilding</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Blonde</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Leiter</surname>
<given-names>LA</given-names>
</string-name>, et al. <article-title>Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus</article-title>. <source xml:lang="en">J Diabetes Complications</source>. <year>2015</year>;<volume>29</volume>:<fpage>438</fpage>&#x02010;<lpage>444</lpage>.<pub-id pub-id-type="pmid">25660137</pub-id></mixed-citation></ref><ref id="dom13296-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom13296-cit-0019">
<string-name>
<surname>Petrykiv</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Greasley</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Persson</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Heerspink</surname>
<given-names>HJL</given-names>
</string-name>. <article-title>Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function</article-title>. <source xml:lang="en">Clin J Am Soc Nephrol</source>. <year>2017</year>;<volume>12</volume>:<fpage>751</fpage>&#x02010;<lpage>759</lpage>.<pub-id pub-id-type="pmid">28302903</pub-id></mixed-citation></ref><ref id="dom13296-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom13296-cit-0020">
<string-name>
<surname>Iemitsu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iizuka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takihata</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin: interim analysis of the ASSIGN&#x02010;K study</article-title>. <source xml:lang="en">J Clin Med Res</source>. <year>2016</year>;<volume>8</volume>:<fpage>373</fpage>&#x02010;<lpage>378</lpage>.<pub-id pub-id-type="pmid">27081422</pub-id></mixed-citation></ref></ref-list></back></article>